Targets › NPC1L1
1 program from 1 company in 10 trials: 7 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Cardiovascular, Immunology; next expected readout Nov 2027.
Plays a major role in cholesterol homeostasis. Critical for the uptake of cholesterol across the plasma membrane of the intestinal enterocyte. (UniProt, Q9UHC9)
Open in Phaseline: the race on NPC1L1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NewAmsterdam Pharma | ezetimibe Niemann-Pick C1-like protein 1 inhibitor | NPC1L1 | Phase 3 | Lipidemia; Atherosclerotic Cardiovascular Disease With Dyslipidemia; Atherosclerotic Cardiovascular Disease (ASCVD); Type 1 Diabetes … | Nov 2027 |
Lipidemia (1) Atherosclerotic Cardiovascular Disease With Dyslipidemia (1) Atherosclerotic Cardiovascular Disease (ASCVD) (1) Type 1 Diabetes (1) Myocardial Infarction (1) Coronary Artery Disease (1) ASCVD (1) Rheumatoid Arthritis (RA) (1) Prostate Cancer (1) Ischemic Stroke (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.